hdr isap 2019

News July 2015

ISAP members invited to comment on EMA's PK/PD guideline
The European Medicines Agency (EMA) invited several ISAP members to a workshop discussing pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal products. The presentations and discussions will support the drafting of the final regulatory guideline on PK/PD of antibacterial agents, as proposed by a concept paper.

News April 2015

2nd International Conference on Polymyxins
After ICAAC/ICC 2015, we invite you to attend the 2nd International Conference on Polymyxins to learn of the latest achievements on all major aspects of the polymyxin antibiotics.

Colistin and polymyxin B are last therapeutic options for treatment of life-threatening infections caused by Gram-negative ‘superbugs', namely Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae. Since the 1st International Conference on Polymyxins in 2013 (Prato, Italy), significant progress has been made in the clinical use and pharmacology of polymyxins, in particular PK/PD/TD and nephrotoxicity, and discovery of novel polymyxin-like antibiotics.

News November 2014

Polymyxin consensus has been published in Lancet Infectious Diseases

The results of the Polymyxin conference in Prato, Italy, May 2013 have been published in Lancet Infectious Diseases:

RL Nation, J Li, O. Cars, W. Couet, MN Dudley, KS Kaye, JW Mouton, DL Paterson, VH Tam, U. Theuretzbacher, BT Tsuji, JD Turnidge: Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus

Continue Reading

News March 2015

Best known for his contribution to the development of PK/PD principles, Dr. William A. Craig has passed away Wednesday March 11, 2015. Dr. Craig was an extraordinary man and a shining star in the fields of infectious diseases and antimicrobial therapy. His passing leaves a large void in our lives and field.
Obituary (D. Andes)

News October 2014

Conference on Reviving Old Antibiotics in Vienna great success!

Almost 300 researchers, academics and representatives from pharmaceutical companies and national medical agencies convened in Vienna for the three day conference entitled ‘Reviving Old Antibiotics’. They reviewed the increasing threat of AMR, and explored the potential benefits and disadvantages of using old, off-patent antibiotics that may still be effective against some pathogens resistant to more modern treatments, with a view to creating an action plan for taking this initiative forward.
More here...